Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020

Edward R Scheffer Cliff; Aaron S Kesselheim; Benjamin N Rome; William B Feldman

doi:10.1001/jamanetworkopen.2023.7467

Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020

JAMA Netw Open. 2023 Apr 3;6(4):e237467. doi: 10.1001/jamanetworkopen.2023.7467.

Authors

Edward R Scheffer Cliff^{1

2}, Aaron S Kesselheim^{1

2}, Benjamin N Rome^{1

2}, William B Feldman^{1

2}

Affiliations

¹ Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.

No abstract available

Plain language summary

This cross-sectional study analyzes trends in Medicare Part D use and spending on oral-targeted drugs for chronic lymphocytic leukemia from 2014 to 2020.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Health Expenditures
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Medicare Part D*
United States